Kynamro

Active Ingredient(s): Mipomersen Sodium
FDA Approved: * January 29, 2013
Pharm Company: * GENZYME CORP
Category: Cholesterol

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kynamro Overview

Mipomersen (INN; trade name Kynamro) is used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the context of a risk management plan. Contents 1 Indications 1.1 Pregnancy and lactation 2 Contraindications 3 Adverse effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 8 References Indications K...

Read more Kynamro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Mipomersen

Recent Kynamro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Mipomersen Sodium

Injection: 200mg/ml
Solution: 200mg/ml (200mg/ml)

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kynamro: (3 results)

Sorted by National Drug Code

58468-0190 Kynamro 200 mg/ml Subcutaneous Injection, Solution by Genzyme Corporation
58468-0191 Kynamro 200 mg/ml Subcutaneous Injection, Solution by Genzyme Corporation
70688-0502 Kynamro 200 mg/ml Subcutaneous Injection, Solution by Kastle Therapeutics LLC

Other drugs which contain Mipomersen Sodium or a similar ingredient: (1 result)

MIPOMERSEN SODIUM